Tag Archives: FDA
Approval of Avastin in Breast Cancer Revoked
The New York Times, November 18, reports the Food and Drug Administration has revoked approval of monoclonal antibody bevacizumab (Avastin) for use in metastatic breast cancer. Highlights of the article, by Andrew Pollack: Pharmaceutical manufacturer Genentech plans another clinical trial … Continue reading
FDA Halts Hip Manufacturers
In an unusual move, the Food and Drug Administration has ordered all producers of a popular category of artificial hip to undertake studies of the implants, which have been linked to high early failure rates and severe health effects in … Continue reading
FDA Endorses New Criteria for Lap Band
The United States Food and Drug Administration recently lowered the prerequisite body mass index from 35 to 30 (in patients with a comorbity) for use of Allergan’s Lap-Band ® Adjustable Gastric Banding System. An article in Bariatric Times, authored by … Continue reading
